Augmented inhibition of angiogenesis by combination of HER2 antibody chA21 and trastuzumab in human ovarian carcinoma xenograft

Journal of Ovarian Research

Volumn 3, Issue 1, 2010, Pages

  Zhang, Anli ^a   Shen, Guodong ^a   Zhao, Ting ^b   Zhang, Guihong ^a   Liu, Jing ^c   Song, Lihua ^a,b   Wei, Wei ^a   Bing, Ling ^a   Wu, Zhengsheng ^a   Wu, Qiang ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b Anhui Anke Biotechnology Co Ltd   (China)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY CHA 21; PROTEIN KINASE B; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROVASCULATURE; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 77956655089     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-3-20     Document Type: Article

References (29)

1. Cancer statistics. A Jemal R Siegel E Ward Y Hao J Xu T Murray MJ Thun, CA Cancer J Clin 2008 58 2 71 96 10.3322/CA.2007.0010 18287387
2. Screening and detection of ovarian cancer. G Breedlove C Busenhart, J Midwifery Womens Health 2005 50 1 51 54 10.1016/j.jmwh.2004.10.002 15637515
3. The distinctive nature of HER2-positive breast cancers. HJ Burstein, N Engl J Med 2005 353 16 1652 1654 10.1056/NEJMp058197 16236735
4. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. DJ Slamon W Godolphin LA Jones JA Holt SG Wong DE Keith WJ Levin SG Stuart J Udove A Ullrich, Science 1989 244 4905 707 712 10.1126/science.2470152 2470152
5. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. E Verri P Guglielmini M Puntoni L Perdelli A Papadia P Lorenzi A Rubagotti N Ragni F Boccardo, Oncology 2005 68 2-3 154 161 10.1159/000086958 16020953
6. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. DB Agus MS Gordon C Taylor RB Natale B Karlan DS Mendelson MF Press DE Allison MX Sliwkowski G Lieberman, J Clin Oncol 2005 23 11 2534 2543 10.1200/JCO.2005.03.184 15699478
7. Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics. JA Wilken KT Webster NJ Maihle, J Ovarian Res 2010 3 7 10.1186/1757-2215-3-7 20346177
8. Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185(c-erbB-2). LS Cheng AP Liu JH Yang YQ Dong LW Li J Wang CC Wang J Liu, Cell Res 2003 13 1 35 48 10.1038/sj.cr.7290149 12643348
9. Codon optimization, expression, and characterization of an internalizing anti-ErbB2 single-chain antibody in Pichia pastoris. S Hu L Li J Qiao Y Guo L Cheng J Liu, Protein Expr Purif 2006 47 1 249 257 10.1016/j.pep.2005.11.014 16403645
10. Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism. S Hu Z Zhu L Li L Chang W Li L Cheng M Teng J Liu, Proteins 2008 70 3 938 949 10.1002/prot.21551 17847085
11. Crystallization and preliminary crystallographic studies of the single-chain variable fragment of antibody chA21 in complex with an N-terminal fragment of ErbB2. Y Liu H Zhou J Zhu Y Gao L Niu J Liu M Teng, Acta Crystallogr Sect F Struct Biol Cryst Commun 2009 65 Pt 7 692 694 10.1107/S1744309109020107 19574641
12. Angiogenesis relates to estrogen receptor negativity, c-erbB-2 overexpression and early relapse in node-negative ductal carcinoma of the breast. MI Koukourakis C Manolas G Minopoulos A Giatromanolaki E Sivridis, Int J Surg Pathol 2003 11 1 29 34 10.1177/106689690301100107 12598915
13. Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. KS Russell DF Stern PJ Polverini JR Bender, Am J Physiol 1999 277 6 Pt 2 2205 2211 10600838
14. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. AM Petit J Rak MC Hung P Rockwell N Goldstein B Fendly RS Kerbel, Am J Pathol 1997 151 6 1523 1530 9403702
15. Icariin stimulates angiogenesis by activating the MEK/ERK-and PI3K/AKT/eNOS-dependent signal pathway in human endothelial cells. BH Chung CK Kim, Biochem Biophys Res Commun 2008 376 404 408 10.1016/j.bbrc.2008.09.001 18789310
16. Anti-HER-2 engineering antibody ChA21 inhibits growth and induces apoptosis of SKOV-3 cells. AL Zhang H Xue XG Ling Y Gao F Yang LS Cheng J Liu Q Wu, Journal of Experimental & Clinical Cancer Research 2010 29 23
17. Tumor inhibition and improved immunity in mice treated with flavone from Cirsium japonicum DC. S Liu X Luo D Li J Zhang D Qiu W Liu L She Z Yang, Int Immunopharmacol 2006 6 9 1387 1393 10.1016/j.intimp.2006.02.002 16846832
18. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. PB Vermeulen G Gasparini SB Fox M Toi L Martin P McCulloch F Pezzella G Viale N Weidner AL Harris, Eur J Cancer 1996 32 A 14 2474 2484 10.1016/S0959-8049(96)00379-6 (Pubitemid 27080786)
19. Akt takes center stage in angiogenesis signaling. S Dimmeler AM Zeiher, Circulation Research 2000 86 1 4 5 10625297
20. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram, New England Journal of Medicine 2001 344 11 783 792 10.1056/NEJM200103153441101 11248153
21. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. DH Roukos, Ann Surg Oncol 2010 17 1 14 17 10.1245/s10434-009-0766-0 19841980
22. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. JN McAlpine KC Wiegand R Vang BM Ronnett A Adamiak M Kobel SE Kalloger KD Swenerton DG Huntsman CB Gilks, Bmc Cancer 2009 9 433 10.1186/1471-2407-9-433 20003286
23. Ten years of HER2-directed therapy: still questions after all these years. IE Krop EP Winer, Breast Cancer Res Treat 2009 113 2 207 209 10.1007/s10549-008-0041-2 18463974
24. HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. KL Blackwell MW Dewhirst V Liotcheva S Snyder G Broadwater R Bentley A Lal G Riggins S Anderson J Vredenburgh, Clin Cancer Res 2004 10 12 Pt 1 4083 4088 10.1158/1078-0432.CCR-03- 0695 15217943
25. HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancer. SF Schoppmann D Tamandl L Roberts G Jomrich A Schoppmann R Zwrtek P Dubsky M Gnant R Jakesz P Birner, Ann Oncol 2009 21 5 955 960 10.1093/annonc/mdp532 19940005
26. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. P Laakkonen M Waltari T Holopainen T Takahashi B Pytowski P Steiner D Hicklin K Persaud JR Tonra L Witte, Cancer Res 2007 67 2 593 599 10.1158/0008-5472.CAN-06-3567 17234768 (Pubitemid 46192197)
27. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. K Lamszus MA Brockmann C Eckerich P Bohlen C May U Mangold R Fillbrandt M Westphal, Clin Cancer Res 2005 11 13 4934 4940 10.1158/1078-0432.CCR-04-2270 16000592
28. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. T Ben-Kasus B Schechter S Lavi Y Yarden M Sela, Proc Natl Acad Sci USA 2009 106 9 3294 3299 10.1073/pnas.0812059106 19218427
29. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. LM Friedman A Rinon B Schechter L Lyass S Lavi SS Bacus M Sela Y Yarden, Proc Natl Acad Sci USA 2005 102 6 1915 1920 10.1073/pnas.0409610102 15684082